How long can you be on Mounjaro for weight management?

What the SURMOUNT trials tell us about staying on tirzepatide long-term

The pivotal SURMOUNT-1 trial ran for 72 weeks, which is roughly 17 months, and participants at the 15 mg dose lost an average of around 20–21% of their body weight over that period. That figure comes from a large, controlled study published in the New England Journal of Medicine and forms the backbone of NICE's assessment. Crucially, weight loss in those trials did not plateau early and then plateau forever; it continued accruing for many participants well into the second half of the study.

The SURMOUNT-4 extension then looked at what happens after stopping. Participants who had been on tirzepatide and then switched to placebo regained a substantial portion of the weight they had lost, while those who continued treatment maintained the majority of their progress. That evidence is part of why prescribers and guidelines treat tirzepatide more like an ongoing management tool than a short course of antibiotics. If you want to understand when you might start to see results during those early weeks, that is a separate but related question worth reading about.

None of this means everyone should stay on Mounjaro indefinitely. It means the question of duration deserves a proper clinical answer rather than a blanket rule.

How UK guidance handles the question of stopping or continuing

NICE's appraisal of tirzepatide, TA1026, published in December 2024 and updated in September 2025, includes one clear review trigger: if fewer than 5% of body weight has been lost after six months at the highest tolerated dose, the clinical case for continuing is reviewed. That is not the same as a mandatory stop at six months. It is a checkpoint designed to avoid keeping someone on treatment that is not working for them. If you are responding well, NICE's own wording supports ongoing use.

Separately, NICE's appraisal of Wegovy (semaglutide) under TA875 does include a two-year maximum for that medicine within NHS specialist services. Mounjaro's TA1026 carries no equivalent cap. The distinction matters if you are comparing the two treatments or considering a switch; you can explore the broader Mounjaro overview for more on how the two licences differ.

For NHS patients, access is phased and criteria are strict. For people using a regulated private service, the licence itself and the clinical picture govern how long treatment continues. Either way, treatment duration is not a decision you make alone.

Practical factors that shape how long you stay on treatment

A few things genuinely influence how long any individual stays on Mounjaro, and they are worth understanding before you start or before you decide to stop. First, how much weight you have to lose and how your body responds to titration both matter. Someone who reaches their health goals quickly and maintains them with significant lifestyle change may have a different conversation with their prescriber than someone managing a chronic condition where weight is one of several interacting factors.

Second, tolerability across the dose schedule plays a role. The starting dose is low precisely to give your body time to adjust; the therapeutic benefit builds as the dose increases over subsequent months. If side effects at a higher dose remain troublesome, the prescriber may hold the dose or consider whether continuing at that level is appropriate. That is a different question from whether to stop altogether, and it is one the duration and weight-loss goals page covers in more detail.

Third, cost is a real-world factor for many people. Private treatment is self-funded. If you are weighing up affordability over time, the Mounjaro pricing page sets out what a full-service private prescription typically includes. One thing worth knowing: ordering by 12pm on a weekday means same-day dispatch once approved, which is useful if you are planning around a Monday start or a holiday period when you do not want a gap in supply.

Fourth, stopping abruptly is something to discuss with your prescriber rather than do unilaterally. Gradual tapering or a supervised pause is a different clinical conversation from simply running out. If you are thinking about what staying on Mounjaro long-term involves, or conversely what a planned break looks like, that conversation belongs in a clinical review, not a forum thread.

What ongoing treatment looks like through a regulated private pharmacy

At nume, every repeat order goes through a fresh clinical review by a GPhC-registered Independent Prescriber. There are no rolling subscriptions and no automatic renewals. Our pharmacy holds GPhC premises registration 9012878, which you can verify directly on the pharmacy register. Evidence of ongoing response is part of what each review considers, and if a prescriber has questions, they ask them before the order goes out.

If you are already on treatment and thinking about getting the most from each stage, that is a practical companion to the duration question. And if you want a broader sense of where Mounjaro sits among available options, the weight-loss treatment overview is worth a read. For anything specific to your own situation, a prescriber conversation is the right place to start. You can speak to our prescribers through a free consultation at any point.